Price Chart

DATE TIME TYPE PERIOD REPORTED
EPS
ESTIMATED
EPS
SURPRISE
03/01/2023* 16:30 EST Earnings Call Q4 2022 -- -- --
03/01/2023* -- Results Q4 2022 -- -0.18 --
11/08/2022 16:30 EST Earnings Call Q3 2022 -- -- --
11/08/2022 -- Results Q3 2022 -0.15 -0.27 44.95%
08/09/2022 16:30 EST Earnings Call Q2 2022 -- -- --
08/09/2022 -- Results Q2 2022 -0.46 -0.29 -56.82%
05/10/2022 16:30 EST Earnings Call Q1 2022 -- -- --
05/10/2022 -- Results Q1 2022 -0.36 -0.33 -9.92%
*Estimated Date/Time

Earnings

Next Report Date 03/01/2023 (est.)
EPS Estimate Upgrade
Last Actual EPS Upgrade

Loading chart...
Last Report Date 11/08/2022
Beat/Miss Upgrade
Return Since -7.48%
Last FQE 09/30/2022
Next FQE 12/30/2022

Profile

Edit
Inovio Pharmaceuticals Inc is a United States based biotechnology company that develops active DNA-based immunotherapies and vaccines to treat and prevent cancers and infectious diseases. The company is engaged in gene therapy, where its immunotherapy platform consists of DNA-based immunotherapy and electroporation delivery technologies.
URL https://www.inovio.com
Investor Relations URL https://ir.inovio.com
HQ State/Province Pennsylvania
Sector Healthcare
Industry Biotechnology
Equity Style Small Cap/Growth
Next Earnings Release Mar. 01, 2023 (est.)
Last Earnings Release Nov. 08, 2022
Next Ex-Dividend Date N/A
Last Ex-Dividend Date N/A

Dividends

Dividend Per Share (TTM) --
2017
2018
2019
2020
2021
No data available
 
6.00%
4.00%
2.00%
 
Yield to Market 0.00
Yield to Sector 0.00
Yield to Industry 0.00
Last Dividend Amt. --
Dividend Frequency --
Last Ex-Dividend Date --
Yield (TTM) 0.00%
Forward Yield --
Payout Ratio 0.00%
Cash Payout Ratio 0.00%
Consistent Payer (5Y) No
Consistent Growth (5Y) No

Ownership

Insider Ownership Percentage Upgrade
Jul '20
Nov '20
Mar '21
 
80.00%
40.00%
10.00%
 

Short Interest

Short Interest Upgrade
Percent of Shares Outstanding Short Upgrade
Jul '20
Nov '20
Mar '21
 
80.00%
40.00%
10.00%
 

Total Returns Comparison

Edit comparables

Annual Total Returns Versus Peers

Edit comparables
Loading chart...
Name
2015
2016
2017
2018
2019
2020
2021
YTD
-26.80%
3.27%
-40.49%
-3.15%
-17.50%
168.2%
-43.62%
-60.32%
1.38%
11.96%
21.83%
-4.38%
31.49%
18.40%
28.71%
-13.26%
-13.39%
-36.60%
-53.96%
-69.82%
-81.36%
1.53K%
9.81%
-79.27%
41.48%
-84.98%
-1.59%
48.39%
-89.18%
2.70K%
28.30%
-88.45%
-68.18%
-52.29%
22.75%
-95.69%
-90.20%
251.9%
148.6%
-64.62%
-67.80%
-28.59%
-49.84%
-47.69%
-93.17%
229.0%
-48.60%
-56.50%
As of December 02, 2022.

Profile

Edit
Inovio Pharmaceuticals Inc is a United States based biotechnology company that develops active DNA-based immunotherapies and vaccines to treat and prevent cancers and infectious diseases. The company is engaged in gene therapy, where its immunotherapy platform consists of DNA-based immunotherapy and electroporation delivery technologies.
URL https://www.inovio.com
Investor Relations URL https://ir.inovio.com
HQ State/Province Pennsylvania
Sector Healthcare
Industry Biotechnology
Equity Style Small Cap/Growth
Next Earnings Release Mar. 01, 2023 (est.)
Last Earnings Release Nov. 08, 2022
Next Ex-Dividend Date N/A
Last Ex-Dividend Date N/A

Ownership

Insider Ownership Percentage Upgrade
Jul '20
Nov '20
Mar '21
 
80.00%
40.00%
10.00%
 

Short Interest

Short Interest Upgrade
Percent of Shares Outstanding Short Upgrade
Jul '20
Nov '20
Mar '21
 
80.00%
40.00%
10.00%
 

Top Fund Holders

Symbol Dollars Invested % Weight
MOON 899319.0 USD 2.72%
F000016ZDA 190.00 USD 1.90%
F00001CY0W 150.00 USD 1.50%

Top Portfolio Holders

0 of 0

Other Resources

Whale Wisdom 13F Filings
Seeking Alpha Call Transcripts
Nasdaq Insider Trading
Nasdaq Institutional Ownership
Nasdaq Option Chain
SEC SEC Filings
Twitter INO Tweets